Table 2.

Risk of malignant tumours in men up to age 99 after a histopathological verified diagnosis of gynecomastia 1970–79. Follow up time includes 1970–1999 (8375.2 years). The cohort consists of 446 men.

Diagnosis		OBS	EXP	SIR	95% Confidence	interval
140–209	All malignant tumours	68	66.07	1.03	0.80	1.30
140	Lip	1	0.70	1.43	0.04	7.97
141_3_4	Oral cavity	0	0.51	0.00	0.00	7.18
142	Parotid glands	0	0.19	0.00	0.00	19.71
145–148	Pharynx, hypopharynx	0	0.42	0.00	0.00	8.69
150	Esophagus	3	0.78	3.82	0.79	11.17
151	Stomach	3	4.09	0.73	0.15	2.15
153	Colon	7	5.43	1.29	0.52	2.66
154	Rectum	0	3.57	0.00	0.00	1.03
1550	Liver and intrahepatic ducts	1	0.94	1.06	0.03	5.90
1551–1559	Gallblader & bile ducts	1	0.67	1.50	0.04	8.34
157	Pancreas	1	1.95	0.51	0.01	2.86
160	Nasal cavities & sinus	0	0.13	0.00	0.00	27.71
161	Larynx	0	0.65	0.00	0.00	5.67
1620–1621	Trachea & lung	6	6.31	0.95	0.35	2.07
1622	Mesothelioma	0	0.31	0.00	0.00	12.04
170	Male breast cancer	0	0.09	0.00	0.00	42.96
177	Prostate	16	16.21	0.99	0.56	1.60
178	Testicle	3	0.52	5.82	1.20	17.00
180	Kidney	1	2.18	0.46	0.01	2.55
181	Urinary bl,.urinary tc.	1	4.85	0.21	0.01	1.15
190	Melanoma	0	1.73	0.00	0.00	2.1
191	Skin excl melanoma	13	4.06	3.21	1.71	5.48
193	Brain & nervous system	1	1.71	0.59	0.01	3.26
194	Thyroid	0	0.30	0.00	0.00	12.43
196–197	Bone & soft tissue	0	0.49	0.00	0.00	7.59
200+202	Non-Hodgkin's lymphoma	1	1.96	0.51	0.01	2.84
201	Hodgkin's disease	0	0.28	0.00	0.00	12.97
203	Multiple myeloma	0	0.90	0.00	0.00	4.11
Acute leukemia		1	0.54	1.86	0.05	10.38
204.1	Chr. lymph. leukemia	0	0.74	0.00	0.00	4.98
205.1	Chr myeloid leukemia	0	0.18	0.00	0.00	20.83
208	Polycythemia vera	0	0.17	0.00	0.00	21.67